Related Experiment Video

Updated: May 16, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Emerging drugs for myelofibrosis

Ehab Atallah1, Srdan Verstovsek

  • 1Medical College of Wisconsin Cancer Center, Neoplastic Diseases and Related Disorders, Department of Internal Medicine, Milwaukee, WI, USA.

Expert Opinion on Emerging Drugs
|November 29, 2012
PubMed
Abstract

Insights

Myelofibrosis (MF) is a JAK/STAT-driven cancer. Ruxolitinib, a JAK inhibitor, effectively reduces spleen size and symptoms, but new treatments are needed to address fibrosis and improve blood counts.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative neoplasm.
  • MF involves dysregulation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling network.
  • Key features include splenomegaly, anemia, and debilitating symptoms due to ineffective hematopoiesis and cytokine release.

Purpose of the Study:

  • To review the pathogenesis, clinical features, and current treatments for MF.
  • To discuss clinical data for ruxolitinib, an approved JAK1/JAK2 inhibitor.
  • To explore emerging therapies for MF.

Main Methods:

  • Literature review of relevant MF articles.
  • Inclusion of abstracts from recent congresses.
  • Synthesis of information on pathogenesis, clinical presentation, and treatment.

Main Results:

  • Ruxolitinib effectively reduces spleen size and alleviates MF symptoms, improving quality of life.
  • Ruxolitinib may increase risks of anemia and thrombocytopenia and does not reverse bone marrow fibrosis.
  • Ongoing studies focus on ruxolitinib dosing and combination therapies.

Conclusions:

  • Ruxolitinib offers significant benefits for MF patients but has limitations.
  • Further research is exploring novel JAK inhibitors and other agents.
  • Emerging therapies aim to improve blood counts and address marrow fibrosis in MF.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...